RTW Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

RTW Investments’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,617,626	Closed	-$20.9M	–	103
2020 Q3	$20.9M	Buy	2,617,626 +17,626	+0.7%	+$154K	0.5%	49
2020 Q2	$26M	Buy	+2,600,000	New	+$16.3M	0.73%	37
2016 Q2	–	Sell	-7,691	Closed	-$63K	–	36
2016 Q1	$63K	Buy	7,691 +636	+9%	+$5.2K	0.02%	32
2015 Q4	$85K	Buy	7,055 +27	+0.4%	+$264	0.03%	35
2015 Q3	$84K	Sell	7,028 -12,972	-65%	-$183K	0.03%	41
2015 Q2	$367K	Buy	+20,000	New	+$343K	0.11%	30

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RTW Investments's ADAP Position: Q4 2020 in Review

RTW Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 2,617,626 shares — an estimated $20.9M sold.

RTW Investments first reported a position in ADAP in Q2 2015 and held it in 6 quarters. The position peaked at $26M in Q2 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

RTW Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
RTW Investments sold 2,617,626 Adaptimmune Therapeutics shares in Q4 2020, an estimated $20.9M.
RTW Investments first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 6 quarters.
RTW Investments's Adaptimmune Therapeutics position peaked at $26M in Q2 2020.
87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on RTW Investments's 13F filing for Q4 2020, filed 16 Feb 2021.